This is the authors' abstract. We don't add key points for this paper.
Background Chimeric antigen receptor (CAR) T-cell therapy has shown limited efficacy against solid tumors due to antigen heterogeneity and scarcity of tumor-specific targets. Methods To address those challenges, we report a covalent CAR-T strategy that achieves programmable tumor recognition via oncolytic adenovirus-mediated (OAD) delivery of artificial antigens. An engineered OAD was designed to induce tumor-selective expression of a membrane-anchored SpyTag-containing artificial antigen on infected tumor cells. In parallel, we generated SpyCatcher CAR-T cells by replacing the conventional single-chain variable fragment (scFv) with SpyCatcher, which forms a spontaneous covalent bond with SpyTag and redirects CAR-T-cell activity toward virus-labeled tumor cells. Results In vitro , optimized SpyCatcher CAR-T cells mediated selective cytotoxicity against SpyTag-positive tumor cells, achieving >85% specific lysis at an effector-to-target ratio of 1:1, while sparing antigen-negative cells. The OAD efficiently induced tumor-selective expression of membrane-anchored SpyTag-fused antigens across multiple cell lines. Combined treatment with OAD and SpyCatcher CAR-T cells resulted in substantially greater antitumor activity than either monotherapy alone. In vivo , the combinatorial strategy significantly inhibited tumor growth and increased intratumor CD3 + , CD8 + T-cell infiltration in both immunodeficient and immunocompetent mouse models. Importantly, patient-derived prostate cancer organoids were effectively transduced by OAD and supported robust SpyCatcher CAR-T cell infiltration and cytotoxicity, demonstrating the translational potential of this approach. Conclusions This study establishes a modular platform for solid tumor immunotherapy therapy by integrating covalent SpyCatcher CAR-T cells with SpyTag-delivering OAD. By decoupling tumor recognition from endogenous antigen expression, this approach provides a generalizable strategy to overcome antigen heterogeneity and scarcity of tumor-specific targets in solid tumors.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: